TRAW · Traws Pharma, Inc.
$0.57
-0.03 (-4.83%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern through the one-year period after the date that the financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.78M
Shares
15.37M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2024-03-14 | MARK GUERIN | Officer | 2,591 | 2024-03-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-03-14 | STEVEN M FRUCHTMAN | Officer, Director | 8,727 | 2024-03-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-02-08 | STEVEN M FRUCHTMAN | Officer, Director | 9,212 | 2024-02-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Showing 1–3 of 3 filings
Key facts
CIK
1130598
CUSIP
68232V884
13F (30d)
39 filings
38 filers
Visit website
Investor relations